Skip to main content
. Author manuscript; available in PMC: 2020 Jan 3.
Published in final edited form as: Gynecol Oncol. 2019 Jun 19;154(2):420–425. doi: 10.1016/j.ygyno.2019.05.013

Table 4.

Multivariate disease-specific survival analysis (N = 7914).

HR 95 CI Log rank

Age ≥59 1.01 1.01 −1.02 0.032
Asian (Caucasian) 0.78 0.64 −0.96 0.017
Body Mass Index (>25) 1.01 1.002221g1.01 −1.01 <0.001
Performance Status of2or3 (0) 1.49 1.33 −1.67 <0.001
Stage III (Stage 1) 7.83 6.29 −9.75 <0.001
Stage IV (Stage 1) 11.46 9.09 −14.4 <0.001
Clear-cell histology (serous) 2.04 1.72 −2.43 <0.001
Grade 3 (Grade 1) 1.38 1.22 −1.57 <0.001
No residual disease (residual) 0.65 0.61 −0.70 <0.001